FRONTEO expands functions of drug discovery support AI system "liGALILEO"

2022.10.03 Press release

--To the press -

FRONTEO expands functions of drug discovery support AI system "liGALILEO"

Added "safety" and "innovativeness" to the target evaluation indicators, realizing more multifaceted analysis

Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Growth)

 FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter referred to as FRONTEO) is pleased to announce the launch of the drug discovery support AI system "li GALILEO(Reading: Ligalileo)" function has been expanded."Safety" and "Innovativeness" have been added to the evaluation items, enabling more multifaceted analysis.

 liGALILEO uses FRONTEO's unique natural language analysis AI engine "Concept Encoder (trademark: conceptencoder, reading: concept encoder)" to identify the potential of genes as drug discovery targets based on a huge amount of article information and medical and pharmaceutical data. It is a system for comprehensive, efficient and objective analysis.By using AI to score and present a wide range of complex evaluation indicators, such as scientific evaluation and marketability evaluation, which are essential for target gene selection, we will improve the efficiency and speed of the work of experts in drug discovery target selection. We support.

 In this function expansion, the existing evaluation items such as linkage between target genes (relevance, causality, sensitivity, dominance), target gene disease area, disease specificity, organ specificity, and cellular level localization will be added. In addition to the information above, it is now possible to analyze the safety and the development status of drugs that target the target gene to comprehensively evaluate the potential for serious toxicity of the target gene.As a result, multifaceted evaluations, which are indispensable in target searches for drug development, can be performed in a much shorter period of time than humans can. A dramatic improvement is expected.

 In drug development, only 2/3 to 1/10 of the target genes/molecules that appear promising in the early stages of development actually make it into the market, and the development period is 15 to 1,000 years. The challenge is that the development cost is about 9 billion yen.In particular, even if a POC (Proof of Concept) trial, in which a drug is administered to humans over an average of nine years from the start of development and proves the efficacy of the drug, the probability of success is low, around 30%.This is thought to be due to factors such as the selection of target genes and molecules for drug discovery that rely on animal experiments and insufficient patient stratification.Improving the probability of success requires a completely new approach, such as the use of AI, in the target search stage, which narrows down target genes and molecules at the top of the drug discovery process.

 FRONTEO realizes efficiency and speed-up of the drug discovery process with an AI engine equipped with an innovative proprietary algorithm, and contributes to improving the probability of success in new drug development and drug repositioning (diversion of existing drugs). I will come.


■ About Concept Encoder
"Concept Encoder" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specializing in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data, including large amounts of free-form text data, based on evidence. "Concept Encoder" can also be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vital signs, and various test values ​​that have been accumulated in the life science field.Patent registration number: Patent No. 6346367


FRONTEO uses the in-house developed AI engine "KIBIT", "Concept Encoder" (trademark: conceptencoder, reading: concept encoder), and "LoocaCross", which specializes in natural language processing. We are a data analysis company that extracts meaningful and important information from large amounts of text data to support corporate businesses. Since its founding in August 2003, it has been operating globally in Japan, the United States, South Korea, and Taiwan, with a focus on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international corporate litigation. has been developed.Based on the AI ​​technology cultivated in this business, since 8 we have expanded our business fields to life science, business intelligence, and economic security. We contribute to solving the problems of various companies, such as drug discovery support, dementia diagnosis support, and financial/personnel/sales support. June 2014, 2007 Listed on Tokyo Stock Exchange Mothers (currently Tokyo Stock Exchange Growth). In January 6, we acquired the first-class medical device manufacturing and sales license (license number: 26B2021X1), and in September of the same year, we submitted a controlled medical device sales business (report number: 13 Minato Misei device No. 1).Capital 10350 thousand yen (as of March 9, 3).

* FRONTEO, liGALILEO, conceptencoder, KIBIT, and Looca Cross are registered trademarks of FRONTEO in Japan.


<Contact information for the press>
Public Relations Officer, FRONTEO Inc.

<Inquiries about Life Science AI Business>
FRONTEO Inc. Life Science AI Business Headquarters

ja 日本語
Machine Translation by Google. : close x